Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

83.34 -1.69 (-1.99%)
Official Closing Price Updated: 4:10 PM EST, Jan 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
69 70 Next >
Wall Street's Next Stock-Split Stocks Are Liable to Be Familiar Names
Nine high-profile stocks -- Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk -- have split since mid-2021. Two of these companies appear ready... 
Via The Motley Fool
Could Eli Lilly's Zepbound Become the World's Best-Selling Drug?
Everyone is excited about Zepbound, from patients to investors... 
Via The Motley Fool
Ozempic Maker's Parent Company To Invest $7B Annually By 2030: 'We Have More Money Than Ever To Invest'
Novo Holdings, the major shareholder of Danish pharmaceutical company Novo Nordisk, plans to ramp up its annual investments to $7 billion by 2030. 
Via Benzinga
Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?
Even more revenue is on the way from additional sales of Wegovy. 
Via The Motley Fool
Don't Worry About Novo Nordisk's Premium Stock Price. It's Still a Buy.
Novo Nordisk stock is up more than 70% in the past year thanks to the success of Ozempic, Rybelsus, and Wegovy. 
Via The Motley Fool
Prediction: 2 Stocks That Could Trounce the Market
They have done it before. 
Via The Motley Fool
LLY Vs NVO: Which One Is Likely To Become A $1T Company First
Tackling growing waistlines is expected to yield much shareholder value. 
Via Talk Markets
This Is What Whales Are Betting On Novo Nordisk
Via Benzinga
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
Novo Nordisk just made a unique acquisition to help bolster the supply of Wegovy and Ozempic. 
Via The Motley Fool
3 Stocks That Could Trounce the Market in 2024
These stocks appear to have what it takes to beat the market this year. 
Via The Motley Fool
S&P 500 Hits 5,000, Magnificent 7 Tops $13 Trillion, Commercial Real Estate Cracks Emerge: The Week In The Markets
The S&P 500 index surged past 5,000, led by tech giants. Tesla falls to ninth in market cap, Novo Nordisk disrupts food industry, Ackman targets retail investors. 
Via Benzinga
Topics Stocks
Exposures US Equities
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
Investors are still excited about obesity treatments and weight-management drugs. 
Via The Motley Fool
What's Going On Eli Lilly Stock Thursday?
Eli Lilly's impressive stock surge, better-than-expected Q4 results, and positive analyst reviews. 
Via Benzinga
Why Catalent Stock Soared Today
Catalent has agreed to be acquired by Novo Nordisk's parent company. 
Via The Motley Fool
The Skinny On Novo Nordisk: Weight-Loss Meds Make Big Pharma A Big Foe For Food Industry
Novo Nordisk's groundbreaking weight-loss treatments are causing concern in the food industry. CEOs are seeking advice from the company. 
Via Benzinga
How Important Are Ozempic and Wegovy to Novo Nordisk's Business?
Does a lack of diversification make Novo Nordisk a risky buy? 
Via The Motley Fool
Catalent's Bloomington Plant Making Novo Nordisk's Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns
Novo Nordisk faces manufacturing challenges and drug shortages for diabetes and weight loss drugs, impacting Wegovy and Ozempic. 
Via Benzinga
Exposures Product Safety
Move Over, Tesla: 5 Stocks That Could Take Its Place in the Magnificent Seven
Tesla is losing its luster as a member of the Magnificent Seven in 2024. Consider one of these other high fliers to take its place. 
Via InvestorPlace
Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks
Thanks to weight loss and obesity drugs, Eli Lilly and Novo Nordisk could become the first trillion-dollar stocks in the pharma industry. 
Via InvestorPlace
Why Novo Nordisk Stock Crushed the Market on Monday
The pharmaceutical giant will receive three manufacturing facilities from its parent company's latest acquisition. 
Via The Motley Fool
NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?
The relaunch of Wegovy last year caused a mad dash by weight loss stocks to compete for market leadership in anti-obesity drugs. 
Via InvestorPlace
Stocks Fall As Traders Dial Back Rate Cut Bets; Dollar, Treasury Yields Rise: What's Driving Markets Monday?
Wall Street ends week on negative note as traders revise down expectations on Fed rate cuts. Strong economic data and Fed officials' comments push stocks into red, reducing rate cut expectations for... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record
Amgen is looking to rival Eli Lilly and Novo Nordisk in weight-loss drugs. 
Via Investor's Business Daily
What's Going On With Eli Lilly Stock Today?
Eli Lilly's stock surge, driven by the upcoming Q4 2023 results and the impact of FDA-approved weight-loss drug Zepbound. 
Via Benzinga
Catalent (CTLT) Stock Pops 10% on Sale to Novo Nordisk
Catalent stock is rising higher on Monday after the company announced a $16.5 billion cash acquisition deal for CTLT shares. 
Via InvestorPlace
Novo Nordisk To Up Production Capacity As Parent Buys Catalent
NVO stock rose after Novo Nordisk's parent, Novo Holdings, said it has agreed to buy contract manufacturer Catalent for $11.5 billion in cash. 
Via Investor's Business Daily
Ozempic Maker Strikes $11B Deal With Catalent As It Rushes To Meet Massive Weight-Loss Drug Demand
This move comes on the heels of the company's recent collaborations to develop new treatment approaches for obesity management and chronic liver diseases. 
Via Benzinga
Is Novo Nordisk a Hot Stock to Buy Now After its Spectacular Q4?
Demand for the company's leading drugs is sky-high, but a giant rival is lying in wait to snatch market share. 
Via The Motley Fool
After a 90% Gain, Is It Too Late to Buy Eli Lilly?
Its drug tirzepatide showed top efficacy as a weight-loss treatment according to the latest real-world data. 
Via The Motley Fool
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
69 70 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.